Furthermore, KRAS mutations in NSCLC have been linked to aberrant activation of the PI3K/Akt and NF-κB pathways [36,37], as well as increased expression of COX-2 [37]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.